This study is in progress, not accepting new patients
Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Los Angeles, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Zev A. Wainberg, MD

Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- Zev A. Wainberg, MD
Zev Wainberg, M.D., holds the Estelle, Abe, and Marjorie Sanders Chair in Cancer Research.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Trishula Therapeutics, Inc.
- Links
- Sign up for this study
- ID
- NCT06119217
- Phase
- Phase 2 Pancreatic Cancer Research Study
- Study Type
- Interventional
- Participants
- About 194 people participating
- Last Updated